monsitj Canaccord Genuity has upgraded Merit Medical Systems (NASDAQ:MMSI) to buy, stating that it sees potential upside for both revenue and EPS estimates for the company. The investment bank said it believes Merit is creating a long-term growth opportunity with its Wrapsody cell-impermeable endoprosthesis once it's FDA approved.

monsitj Canaccord Genuity升级了Merit Medical Systems（纳斯达克股票代码：MMSI）进行收购，表示该公司的收入和每股收益估计都有潜在的上升空间。这家投资银行表示，一旦获得FDA批准，其Wrapsody细胞不透水内假体将为Merit创造长期增长机会。

It sees Merit submitting the final module for its market application at the end of Q2 2024. The investment bank also said it believes Merit could issue “strong” long-range guidance in February. Canaccord added that it sees Merit as relatively undervalued for a mid-cap Med-Tech and raised its price target to $100 from $76.

它认为值得在2024年第二季度末提交最终模块用于市场应用。这家投资银行还表示，它认为Merit可能在2月份发布“强有力的”长期指导。Canaccord补充称，它认为中等市值的医疗科技的价值相对被低估，并将目标价格从76美元提高到100美元。

More on Merit Medical Systems Merit Medical Caught Up In The Med-Tech Downswing Merit Medical Systems, Inc. (MMSI) Q3 2023 Earnings Call Transcript Merit Medical Systems, Inc. 2023 Q3 - Results - Earnings Call Presentation Merit Medical announces process for chief executive officer succession planning Merit Medical proposes private placement of $550M of convertible senior notes .

Med Tech Downswing Merit Medical Systems，Inc.（MMSI）2023年第三季度收益通话记录Merit Medical Systems，Inc.2023年第三季度-结果-收益通话介绍Merit Medical宣布首席执行官继任计划流程Merit Medical提议私募5.5亿美元可转换高级票据。